Share on StockTwits
 

Sangamo BioSciences (NASDAQ:SGMO) CMO Dale G. Ando unloaded 15,000 shares of the stock on the open market in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $18.58, for a total transaction of $278,700.00. Following the transaction, the chief marketing officer now directly owns 97,015 shares of the company’s stock, valued at approximately $1,802,539. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Sangamo BioSciences (NASDAQ:SGMO) traded up 1.20% during mid-day trading on Wednesday, hitting $19.33. The stock had a trading volume of 1,099,001 shares. Sangamo BioSciences has a 52-week low of $6.86 and a 52-week high of $20.33. The stock’s 50-day moving average is $15.78 and its 200-day moving average is $11.82. The company’s market cap is $1.195 billion.

A number of analysts have recently weighed in on SGMO shares. Analysts at Wedbush raised their price target on shares of Sangamo BioSciences to $22.00 in a research note to investors on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Sangamo BioSciences presently has an average rating of “Buy” and a consensus price target of $18.75.

Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.